IRIS - Res&Arch Institutional Research Information System - Research & Archive

MARTELLI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.958
AS - Asia 4.810
EU - Europa 4.734
SA - Sud America 824
AF - Africa 133
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 11
Totale 16.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.827
SG - Singapore 2.222
IT - Italia 1.103
IE - Irlanda 712
BR - Brasile 630
CN - Cina 630
RU - Federazione Russa 604
HK - Hong Kong 598
VN - Vietnam 527
SE - Svezia 490
UA - Ucraina 482
DE - Germania 334
FI - Finlandia 274
FR - Francia 250
KR - Corea 201
GB - Regno Unito 152
IN - India 101
TR - Turchia 88
AR - Argentina 77
BD - Bangladesh 77
CA - Canada 62
IQ - Iraq 57
AT - Austria 51
NL - Olanda 46
ZA - Sudafrica 43
MX - Messico 39
CO - Colombia 35
ID - Indonesia 35
PL - Polonia 33
UZ - Uzbekistan 33
BE - Belgio 32
LU - Lussemburgo 31
CZ - Repubblica Ceca 29
PH - Filippine 29
CH - Svizzera 26
PK - Pakistan 25
JP - Giappone 24
SA - Arabia Saudita 24
ES - Italia 22
MA - Marocco 22
EC - Ecuador 21
LB - Libano 15
VE - Venezuela 15
RO - Romania 14
LT - Lituania 13
AZ - Azerbaigian 12
CL - Cile 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
ET - Etiopia 11
IL - Israele 10
JO - Giordania 10
KE - Kenya 10
MY - Malesia 10
TH - Thailandia 10
BO - Bolivia 9
GR - Grecia 9
AU - Australia 8
EG - Egitto 8
EU - Europa 8
KZ - Kazakistan 8
NP - Nepal 8
OM - Oman 8
TN - Tunisia 8
PE - Perù 7
KG - Kirghizistan 6
PA - Panama 6
AL - Albania 5
DZ - Algeria 5
QA - Qatar 5
UY - Uruguay 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GE - Georgia 4
AO - Angola 3
BH - Bahrain 3
CI - Costa d'Avorio 3
JM - Giamaica 3
KW - Kuwait 3
LK - Sri Lanka 3
NI - Nicaragua 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SN - Senegal 3
UG - Uganda 3
BG - Bulgaria 2
BY - Bielorussia 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IR - Iran 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
MZ - Mozambico 2
TZ - Tanzania 2
Totale 16.452
Salva come PNG Salva come JPEG
Città #
Singapore 1.581
Chandler 768
Dublin 712
San Jose 618
Hong Kong 598
Perugia 498
Ashburn 440
San Mateo 369
Boardman 288
Santa Clara 239
Jacksonville 223
Dong Ket 216
Moscow 212
Seoul 200
Lauterbourg 173
Altamura 161
Beijing 158
Medford 157
Princeton 153
Wilmington 124
Lawrence 118
Munich 117
Andover 113
Ann Arbor 109
Ho Chi Minh City 108
Los Angeles 108
New York 94
Helsinki 92
The Dalles 69
Des Moines 67
Piscataway 64
Turku 59
Hanoi 57
São Paulo 56
Council Bluffs 47
Orem 43
Izmir 42
Saint Petersburg 41
Frankfurt am Main 36
Rome 34
Dallas 33
Brussels 32
Falls Church 32
Belo Horizonte 30
Dudelange 30
Brooklyn 29
Johannesburg 28
Milan 28
Redmond 28
San Francisco 28
Norwalk 27
Pisa 26
Rio de Janeiro 26
Baghdad 25
Nuremberg 25
San Paolo di Civitate 25
London 24
Woodbridge 24
Tokyo 23
Chennai 22
Houston 22
Amsterdam 21
Denver 21
Montreal 21
Shanghai 20
Tashkent 20
Vienna 20
Chicago 19
Warsaw 19
Dhaka 18
Haiphong 18
Phoenix 18
Redwood City 18
Boston 17
Stockholm 16
Mexico City 15
Poplar 15
Atlanta 14
Bologna 14
Florence 14
Foligno 14
Jakarta 14
Falkenstein 13
Manchester 13
Manila 13
Auburn Hills 12
Hefei 12
New Delhi 12
Toronto 12
Ankara 11
Barnet 11
Bucharest 11
Da Nang 11
Baku 10
Brno 10
Buenos Aires 10
Charlotte 10
Columbus 10
Dearborn 10
Guangzhou 10
Totale 10.496
Salva come PNG Salva come JPEG
Nome #
Class IA PI3Ks regulate subcellular and functional dynamics of IDO1 211
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 178
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 174
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 172
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 159
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) 152
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. 147
Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells. 146
Maesopsin 4-O-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN! and BCAS3 in acute myeloid leukemia 144
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. 140
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification 139
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 139
ARPIR: automatic RNA-Seq pipelines with interactive report 135
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features 132
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 130
Mutant NPM1 Maintains the Leukemic State through HOX Expression 129
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 129
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 129
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia 128
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 126
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 126
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. 121
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 121
Glucocorticoid-induced activation of caspase-8 protects the glucocorticoid-induced protein Gilz from proteasomal degradation and induces its binding to Sumo-1 in murine thymocytes 118
Acute Myeloid Leukemia with mutated nucleophosmin (NPM1). Any hope for a targeted therapy? 118
Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia 117
Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse 117
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML 116
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia 115
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 114
Exon-12 nucleophosmin (NPM) mutation and aberrant cytoplasmic expression of NPM protein in leukemia cell line OCI-AML3 113
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants 112
Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants 112
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 111
Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. 111
From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo [4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia 111
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. 110
EML4-ALK rearrangement in non-small-cell lung cancer and non-tumor lung tissues. 109
Pharmacological modulation of caspase-8 in thymus-related medical conditions. 109
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 109
BRAF mutations in hairy-cell leukemia. 108
Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. 108
Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin 108
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 108
Mechanism of altered nucleo-cytoplasmic traffic of nucleophosmin in acute myelogenous leukemia carrying exon12 NPM mutations (NPMc plus AML) 107
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 107
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 107
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia 106
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. 105
THE BRAF-MEK-ERK PATHWAY IN HAIRY CELL LEUKEMIA: A COMPREHENSIVE DISSECTION IN PRIMARY LEUKEMIC CELLS OF ITS BIOLOGICAL AND THERAPEUTIC RELEVANCE 105
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 104
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 103
WESTERN BLOT IDENTIFICATION OF NPM1 LEUKEMIC MUTANTS IN CYTOLOGICAL AML SAMPLES: A POWERFUL DIAGNOSTIC TECHNIQUE 103
CD123 (IL-3R alpha) IS CONSISTENTLY EXPRESSED ON ACUTE MYELOID LEUKEMIA (AML) CARRYING NUCLEOPHOSMIN (NPM1) GENE MUTATION 103
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia 103
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. 102
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 101
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype 101
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 101
Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission? 100
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. 100
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. 100
HLA-MATCHED TREG/TCON ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ENSURES REMARKABLE CHRONIC GVHD/LEUKEMIA FREE SURVIVAL IN HIGH-RISK LEUKEMIA PATIENTS 100
Cellular and Molecular Biology of Lymphoid Cell 98
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 98
Biological and therapeutic relevance of the BRAF-MEK-ERK pathway in hairy cell leukemia 98
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 97
Failure of gelsolin overexpression to regulate lymphocyte apoptosis. 97
Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. 97
Current status and future perspectives in targeted therapy of NPM1-mutated AML 96
ADOPTIVE IMMUNOTHERAPY WITH REGULATORY AND CONVENTIONAL T CELLS AFFORDS HIGH RATE OF CHRONIC GVHD/RELAPSE-FREE SURVIVAL IN ACUTE MYELOID LEUKEMIA AFTER MYELOABLATIVE HAPLOIDENTICAL TRANSPLANTATION 96
Poor risk acute myelogenous leukemia patients undergoing the Fludarabine-Cytosine Arabinoside-Filgrastim regimen: multidrug resistance expression, granulocyte colony-stimulating factor priming activity and clinical response. 96
CYTOPLASMIC MUTATED NUCLEOPHOSMIN DEFINES THE MOLECULAR STATUS OF A SIGNIFICANT FRACTION OF MYELOID SARCOMAS 96
Stem cell mobilization in normal donors. 95
Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. 95
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. 95
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice 95
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 95
The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor 94
The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. 94
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin 94
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients 92
Fibrin-associated large B-cell lymphoma: first case report within a cerebral artery aneurysm and literature review 92
Whole-Exome Sequencing Identifies Recurrent Mutations of BCOR in Acute Myeloid Leukemia with Normal Karyotype 92
CD123 Is Consistently Expressed on NPM1-Mutated AML Cells 91
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma 91
BRAF V600E mutation in hairy cell leukemia: From bench to bedside 91
MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. 90
Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family. 90
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 90
Absence of nucleophosmin leukemic mutants in B and T cells from AML with NPM1 mutations: Implications for the cell of origin of NPMC plus AML 89
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 89
Actinomycin d targets npm1c-primed mitochondria to restore pml-driven senescence in aml therapy 89
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 88
ADDITION OF THIOTEPA IMPROVES RESULTS IN T-CELL DEPLETED BONE-MARROW TRANSPLANT FOR ADVANCED LEUKEMIA 87
Role of caspase-8 in thymus function 87
NPM1-mutated AML: targeting by disassembling 86
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 86
Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. 85
Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation 84
Totale 11.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.483
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.483
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 0 0 0 0 57 113 245
2021/20221.570 41 299 23 80 64 23 17 394 30 130 239 230
2022/20232.503 167 459 24 200 203 289 5 111 916 35 69 25
2023/20241.063 54 112 66 21 10 7 249 12 83 49 196 204
2024/20253.014 109 251 164 136 371 131 170 244 541 163 482 252
2025/20266.218 445 393 287 771 891 620 1.014 401 791 605 0 0
Totale 17.065